151 related articles for article (PubMed ID: 34658561)
1.
Agrawal A; Prakash A; Choudhury S; Mv M; Jain Y; Purandare N; Puranik A; Shah S; Rangarajan V
Indian J Nucl Med; 2021; 36(3):319-326. PubMed ID: 34658561
[TBL] [Abstract][Full Text] [Related]
2.
Agrawal A; Prakash A; Choudhury S; Manikandan MV; Jain Y; Purandare N; Puranik A; Shah S; Rangarajan V
Indian J Nucl Med; 2021; 36(2):195-200. PubMed ID: 34385794
[TBL] [Abstract][Full Text] [Related]
3. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination.
Rangaswamy B; Fardanesh MR; Genden EM; Park EE; Fatterpekar G; Patel Z; Kim J; Som PM; Kostakoglu L
Laryngoscope; 2013 Nov; 123(11):2664-9. PubMed ID: 23553147
[TBL] [Abstract][Full Text] [Related]
4. Musculoskeletal Pitfalls on Fluorodeoxyglucose F 18 PET-Computed Tomography: Pictorial Review.
Asadoorian M; Matcuk GR; Patel DB; Tomasian A; Wassef HR; White EA
PET Clin; 2018 Oct; 13(4):587-607. PubMed ID: 30219190
[TBL] [Abstract][Full Text] [Related]
5. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
6. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Various Orbital Malignancies.
Natarajan A; Chandra P; Purandare N; Agrawal A; Shah S; Puranik A; Rangarajan V
Indian J Nucl Med; 2018; 33(2):118-124. PubMed ID: 29643671
[TBL] [Abstract][Full Text] [Related]
7. Atypical
Childs L; Thompson A; Jones H; Hameeduddin A; Ghufoor K; Adams A
Clin Imaging; 2018; 49():136-143. PubMed ID: 29414508
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
10. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in the Postoperative Period: Utility, Expected Findings, Complications, and Pitfalls.
Garg G; Benchekroun MT; Abraham T
Semin Nucl Med; 2017 Nov; 47(6):579-594. PubMed ID: 28969758
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
13.
Han EJ; O JH; Yoo IR; Kim YS; Kim MS; Kang JH; Choi WH
Hell J Nucl Med; 2017; 20(2):134-140. PubMed ID: 28697190
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
[TBL] [Abstract][Full Text] [Related]
15. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
16.
Ravikanth R
World J Nucl Med; 2021; 20(1):7-16. PubMed ID: 33850484
[TBL] [Abstract][Full Text] [Related]
17. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
18. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT Pitfalls in Gynecologic and Genitourinary Oncologic Imaging.
Lakhani A; Khan SR; Bharwani N; Stewart V; Rockall AG; Khan S; Barwick TD
Radiographics; 2017; 37(2):577-594. PubMed ID: 28287942
[TBL] [Abstract][Full Text] [Related]
20. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
